HGEN - Humanigen's lenzilumab selected for COVID-19 study initiated by NIH

The National Institute of Allergy and Infectious Diseases ((NIAID)), part of the National Institutes of Health ((NIH)) has launched ACTIV-5 Big Effect trial, to compare different investigational therapies to a common control arm to determine which experimental treatments have relatively large effects.The Phase 2 trial will enroll hospitalized COVID-19 volunteers at as many as 40 U.S sites; ~100 subjects will be assigned to each study arm with each of the study sites testing no more than three investigational treatments at once.The trial will test Boehringer Ingelheim's monoclonal antibody risankizumab, in conjunction with the antiviral drug Gilead's remdesivir, compared to a placebo plus remdesivir. The trial will also test the investigational monoclonal antibody Humanigen's ([[HGEN]] -1.4%) lenzilumab, with remdesivir, compared to placebo and remdesivir.The primary purpose of the ACTIV-5/BET study is to evaluate the clinical efficacy of the different investigational therapeutics relative to the control arm on the volunteers’ clinical status at day 8. Secondary

For further details see:

Humanigen’s lenzilumab selected for COVID-19 study initiated by NIH